Can Synbiotics Reduce Rheumatoid Arthritis Symptoms? 
November 2, 2017
Psoriasis (PsO) patients at higher risk for serious liver disease
November 2, 2017
Show all

Multiple Sclerosis Extension Study Shows Long-term Benefits of Lemtrada

The multiple sclerosis medication Lemtrada shows long-term benefits.

A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada (alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing the progression of the disease.

Importantly, most patients required only the standard two-phase treatment course. Few needed additional courses because of relapse or new brain lesions.

The study, “Alemtuzumab CARE-MS I 5-year follow-up,” looked at data from the CARE-MS I Phase 3 clinical trial (NCT00530348) and its extension (NCT00930553), which followed patients for up to five years.

The vast majority, 95.1 percent, of the 367 patients treated in the initial study continued in the extension trial, with 96 percent of these remaining for its entire length of five years. The results were published in the journal Neurology.

Read full article: Multiple Sclerosis Extension Study Shows Long-term Benefits of Lemtrada

Read Full Article: Multiple Sclerosis Extension Study Shows Long-term Benefits of Lemtrada

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.